Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Oct;20(5):293-7.
doi: 10.1016/j.jpag.2007.04.008.

Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis

Amy D Divasta  1 , Marc R Laufer, Catherine M Gordon
Affiliations

Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis

Amy D Divasta et al. J Pediatr Adolesc Gynecol. 2007 Oct.

Abstract

Study objective: To evaluate the bone density of adolescents with endometriosis treated with a GnRH-agonist and "add-back" therapy with norethindrone acetate.

Design: Retrospective chart review.

Setting: Pediatric gynecology clinic at a tertiary care center.

Participants: 36 adolescents, ages 13 to 21 years, with endometriosis.

Main outcome measures: Bone mineral density (BMD, g/cm(2)) by dual energy x-ray absorptiometry (DXA); BMD Z-scores of hip and spine.

Results: The mean BMD Z-score at the total hip was -0.24 +/- 1.0, with a range of -2.4 to 1.7. At this site, 6 subjects had a BMD Z-score between -1.0 and -2.0 SD, while 2 had a Z-score < or = -2.0 SD. The mean BMD Z-score at the lumbar spine was 0.55 +/- 1.1, with a range of -2.8 to 1.4. At the spine, 11 subjects had a BMD Z-score between -1.0 and -2.0 SD, while 3 had a Z-score < or = -2.0 SD. There was no correlation noted between duration of therapy with the GnRH-agonist plus add-back and BMD at the hip or spine.

Conclusion: BMD at the hip was normal in most adolescents with endometriosis who were receiving a GnRH-agonist plus add-back therapy with norethindrone acetate. Almost one third of subjects exhibited skeletal deficits at the spine. These data suggest that BMD should be carefully monitored in adolescents receiving treatment with GnRH agonists.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A. Distribution of BMD Z-scores at the total hip. 6 subjects had an intermediate BMD Z-score; 2 subjects had a low BMD Z-score; B. Distribution of BMD Z-scores at the lumbar spine. 11 subjects had an intermediate BMD Z-score; 3 subjects had a low BMD Z-score.
Fig. 2
Fig. 2
Association between BMD at the total hip and duration of therapy with leuprolide/norethindrone acetate.
Fig. 3
Fig. 3
Association between BMD at the total hip and BMI. BMI: Body mass index, kg/m2.
Fig. 4
Fig. 4
Mean BMD Z-score at the total hip and lumbar spine.
See this image and copyright information in PMC

References

    1. ACOG Committee Opinion. Endometriosis in adolescents. Obstet Gynecol. 2005;105:921. Number 310, April 2005. - PubMed
    1. Laufer MR, Goitein L, Bush M, et al. Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol. 1997;10:199. - PubMed
    1. Surrey ES. Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group. Fertil Steril. 1999;71:420. - PubMed
    1. Kanis JA. Assessment of fracture risk: Who should be screened? In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington: American Society for Bone and Mineral Research; 2003. pp. 316–323.
    1. Amama EA, Taga M, Minaguchi H. The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover. J Clin Endocrinol Metab. 1998;83:333. - PubMed

Publication types